Business
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen’s 46th Annual Health Care Co
About this update from Grace Therapeutics, Inc.
[{"type":"image","alt":"Grace Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Grace Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":238,"height":52,"url":"https://media.zenfs.com/en/globenewswire.com/d9c2bb0e1d56296ef30bd84c47a14138"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sz8Ci7mRHoF.VDufghVM3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d9c2bb0e1d56296ef30bd84c47a14138","width":238,"height":52}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen’s 46th Annual Health Care Conference, to be held March 2-4, 2026 in Boston, MA.","length":551,"tagName":"p"},{"type":"text","content":"Mr. Kohli’s presentation is schedule for March 4, 2026 at 10:30 AM Eastern Time. To register for the webcast, click here. An archived replay will be available for 90 days following the event.","length":191,"tagName":"p"},{"type":"text","content":"In addition, Mr. Kohli will participate in one-on-one and group investor meetings.","length":82,"tagName":"p"},{"type":"text","content":"About aneurysmal Subarachnoid Hemorrhage (aSAH)","length":47,"tagName":"p"},{"type":"text","content":"aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is a relatively uncommon type of stroke (aSAH) that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients.","length":390,"tagName":"p"},{"type":"text","content":"About GTx-104","length":13,"tagName":"p"},{"type":"text","content":"GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates a...